British health authorities have approved the initiation of human clinical trials for an experimental Ebola vaccine, marking the first of four vaccines under development to reach this stage. The vaccine was created by researchers at the University of Oxford following a public health emergency declaration on 17 May.
The ongoing Ebola outbreak, predominantly affecting the Democratic Republic of the Congo, has resulted in 625 deaths and 1,792 laboratory-confirmed cases. The outbreak is caused by the Bundibugyo species of Ebola, a variant that requires its own distinct treatment and vaccine approach, as no approved therapeutics currently exist for this particular strain. The epidemic continues to spread in a conflict zone with highly mobile populations, underscoring the urgency for vaccine development.
The trial will enroll 50 healthy adults aged 18-55 in the UK, with researchers also preparing for trials in Uganda. Participants will be monitored for a year, though scientists expect to gather meaningful data on immune response and potential side effects relatively quickly. The Oxford team leveraged existing viral vector technology—the same platform used in the Oxford-AstraZeneca Covid-19 vaccine—to compress the typical vaccine development timeline from approximately a decade to several weeks. The approach involves using a modified chimpanzee cold virus to deliver genetic code from the Bundibugyo Ebola species, prompting the body’s immune system to mount a defensive response.
The vaccine candidate has undergone testing in animal models and is being manufactured to clinical standards by the Serum Institute of India, which has stockpiled approximately 620,000 doses. Researchers emphasized that while development timelines have been accelerated through parallel workstreams, all standard safety and efficacy testing procedures remain in place. Officials acknowledged the vaccine may carry similar risks to the Oxford-AstraZeneca Covid vaccine, which was associated with rare blood clots in up to one in 100,000 recipients, though they note this risk remains substantially lower than the mortality rate of Bundibugyo Ebola, which kills approximately one-third of those infected.
Three additional vaccine candidates are in development by other organizations, including Moderna using messenger RNA technology and initiatives from the International Aids Vaccine Initiative and Public Health Vaccines employing proven techniques for other Ebola species variants.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI